title: [A case of primary testicular diffuse large B-cell lymphoma with a p53 gene point mutation].
abstract: A 52-year-old man with bilateral swelling in the scrotum was referred to the department of urology in our hospital in January 2013. Pathological examination of the scrotum revealed diffuse large B-cell lymphoma(DLBCL). Immunohistochemical staining revealed p53 overexpression, and polymerase chain reaction-single strand conformation polymorphism(PCRSSCP) revealed a point mutation in exon 7 of the p53 gene. Rituximab plus cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisolone(R-CHOP)therapy and intrathecal prophylaxis were initiated. After three courses of R-CHOP therapy, high-dose cytarabine was administered, followed by peripheral blood stem cell harvesting. Busulfan, etoposide, and Ara-C(BEA)therapy was then administered, followed by autologous peripheral blood stem cell transplantation(auto- PBSCT). Primary testicular lymphoma(PTL)is a rare, clinically aggressive form of extranodal lymphoma, and there is a high incidence rate of relapse in the central nervous system(CNS). The vast majority of cases are histologically DLBCL. The p53 mutation is an independent marker of poor prognosis in patients with DLBCL treated with R-CHOP therapy. Our patient has been disease free for 17 months after auto-PBSCT with high-dose chemotherapy, which results in a greater level of penetration into the CNS.
authors.affiliation: Dept. of Gastroenterology and Hematology/Clinical Oncology, Internal Medicine, Steel Memorial Muroran Hospital.
authors.forename: Makoto
authors.initials: M
authors.lastname: Usami
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kuroda
authors.forename: Saori
authors.initials: S
authors.lastname: Shimoyama
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yoshida
authors.forename: Michiko
authors.initials: M
authors.lastname: Yamada
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Abe
authors.forename: Tamaki
authors.initials: T
authors.lastname: Sakurai
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Fujii
authors.forename: Masahiro
authors.initials: M
authors.lastname: Maeda
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Wakabayashi
authors.forename: Kenichi
authors.initials: K
authors.lastname: Tsukamoto
authors.forename: Miri
authors.initials: M
authors.lastname: Fujita
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Kanari
authors.forename: Koichi
authors.initials: K
authors.lastname: Takada
authors.forename: Junji
authors.initials: J
authors.lastname: Kato
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005091:Exons; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D017354:Point Mutation; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D000069283:Rituximab; D013736:Testicular Neoplasms / Q000235:genetics* / Q000628:therapy; D014182:Transplantation, Autologous; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone